Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06339008 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
A Phase 3 study of Perennial Allergic Rhinitis (PAR), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06339008: Recruiting Phase 3 study of Perennial Allergic Rhinitis (PAR), sponsored by Eli Lilly and Company.
NCT06339008 is a Phase 3 study of Perennial Allergic Rhinitis (PAR) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06339008, a Phase 3 study of Perennial Allergic Rhinitis (PAR), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
Primary Outcome
Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3650150
- DRUG Standard therapy for INCS
Study Locations (20)
California
- Allergy and Asthma Specialists Medical Group - Huntington Beach
- 310 Clinical Research - Inglewood
- Allergy & Asthma Associates of Southern California dba. Southern California Research - Laguna Niguel
- Allergy and Asthma - San Diego
New Jersey
- Circuit Clinical/Hudson-Essex Allergy - Belleville
- Circuit Clinical/Mercer Allergy and Pulmonary Associates - Hamilton
- Dr. Patrick Perin - Teaneck
Florida
- Allergy and Asthma Diagnostic Center - Tallahassee
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
- Asthma Allergy Center of Chicago - River Forest
Missouri
- University of Missouri Hospital - Columbia
- Allergy and Asthma Consultants - St Louis
Colorado
- Asthma and Allergy Associates, PC - Colorado Springs
Kentucky
- Bluegrass Allergy Research - Lexington
Michigan
- Respiratory Medicine Research Institute of Michigan, PLC - Ypsilanti
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-04-26 |
| Est. Completion | 2028-10 |
| Phase | Phase 3 |
What NCT06339008 shows while recruiting
NCT06339008 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Perennial Allergic Rhinitis (PAR) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06339008 names 20 study sites across 12 states, led by California, New Jersey, Florida.
Frequently Asked Questions
What is clinical trial NCT06339008 about?
NCT06339008 is a clinical study titled "A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)". The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
What is the current status of trial NCT06339008?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-04-26. Estimated completion is 2028-10.
What conditions does trial NCT06339008 study?
This clinical trial studies the following conditions: Perennial Allergic Rhinitis (PAR).
What interventions are being tested in trial NCT06339008?
The interventions under investigation include: Placebo (DRUG), LY3650150 (DRUG), Standard therapy for INCS (DRUG).
Who is sponsoring clinical trial NCT06339008?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06339008 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06339008's enrollment target sits among peer trials
450 838th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI